| Catalog No. | DY328018 |
|---|
| Sample type | Plasma, Serum |
|---|
| Sensitivity | 0.156 μg/ml |
|---|
| Range | 0.31-5 μg/mL |
|---|
| Accession | P05231 |
|---|
| Applications | ELISA |
|---|
| Detection method | Colorimetric |
|---|
| Assay type | Quantitative |
|---|
| Recovery | 80-120% |
|---|
| Shipping | 2-8 ℃ |
|---|
| Stability and Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
|---|
| Specifications | Clazakizumab |
|---|
| Alternate Names | ALD-518, BMS-945429, CAS: 1236278-28-6 |
|---|
| Background | Clazakizumab, a humanized anti–IL-6 mAb, is used in the phase II clinical trial for the treatment of RA patients. It has also been evaluated for the treatment of non-small cell lung cancer (NSCLC) and patients with head and neck cancer. |
|---|
| Note | For Research Use Only. |
|---|
